Author:
Zhu Yuhan,Song Maifen,Chen Tengfei,Yang Zhihai,Liu Yanyan
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Giovanna L, Massimo V (2021) FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease. Eur Heart J 47:47
2. Sridhar VS, Liu H, Cherney D (2021) Finerenone—a new frontier in renin-angiotensin-aldosterone system inhibition in diabetic kidney disease. Am J Kidney Dis 78(2):309–311
3. Slomski A (2021) Finerenone for patients with CKD and type 2 diabetes. JAMA, J Am Med Assoc 325(8):713
4. Katayama S, D Yamada, Nakayama M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications, 2017, 31(4):758–765.
5. Bakris GL, Agarwal R, Chan JC et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884–894
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献